Autopsy report · NCT02472080

Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study

“inefficiency”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Thyroid Cancer

Interventions

gemcitabine -oxaliplatine combination

Participants

21

Sites

1

Countries

France

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.